The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is…
Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1…
Marketed DMTs for multiple sclerosis deliver a high level of efficacy in preventing relapses and relapse-associated worsening of disability (RAW). However, MS patients still experience disability…
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants in established classes such as TG Therapeutics’ Briumvi, Novartis’s Kesimpta,…
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants in established classes such as TG Therapeutics’ Briumvi, Novartis’s Kesimpta,…
Immune checkpoint inhibitors have greatly altered the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to treatment of advanced disease, the…
The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is…
The therapeutic portfolio includes the descriptive content of the company’s therapy area such as franchise profile, sales analysis, pipeline analysis, deal and key events.
Growth hormone deficiency (GHD) is characterized by slow growth or absence of growth, short stature, and absent or delayed sexual development. Accurately testing for GHD is challenging and often…
Growth hormone deficiency (GHD) is characterized by slow growth or absence of growth, short stature, and absent or delayed sexual development. Accurately testing for GHD is challenging and often…
The approvals of anti-PD-1/PD-L1 therapies—Keytruda (Merck & Co.), Opdivo (Bristol Myers Squibb), and Bavencio (Merck KGaA)—and antibody-drug conjugates—Padcev (Seagen / Astellas) and…
The approvals of anti-PD-1/PD-L1 therapies—Keytruda (Merck & Co.), Opdivo (Bristol Myers Squibb), and Bavencio (Merck KGaA)—and antibody-drug conjugates—Padcev (Seagen / Astellas) and…
Roche / Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS)—making it the first agent to…
Roche / Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS)—making it the first agent to…